The U.S. Health Resources and Services Administration (HRSA) said this morning it “respectfully disagrees with” and “continues to evaluate its options” about a federal district judge’s Nov. 5 finding that drug manufacturers Novartis and United Therapeutic’s 340B contract pharmacy policies “had not violated” the 340B statute.
HRSA also said it is pleased with two different federal judges’ opinions agreeing with HRSA’s findings that manufacturers Lilly, Novo Nordisk, and Sanofi’s 340B contract pharmacy policies “have unlawfully restricted access to 340B discounted drugs by covered entities that dispense medications through contract pharmacy arrangements—the core finding of HRSA’s May 17, 2021, Violation Letters.”
The U.S. Health Resources and Services Administration (HRSA) said this morning it “respectfully disagrees with” and “continues to evaluate its options” about a federal district judge’s Nov. 5 finding that drug manufacturers Novartis and United Therapeutic’s 340B contract pharmacy policies “had not violated” the 340B statute.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
